Glucovation and Dexcom Settle Dispute Over Intellectual Property Rights

Share Article

Glucovation, Inc. and DexCom, Inc. have agreed to settle their respective lawsuits against one another on mutually agreeable terms, and on April 22, 2016 an Order of the Court allowing the Complaint and Cross-Complaint to be dismissed with prejudice.

“We are very excited about this recent settlement with Dexcom as it will allow us to execute on our vision of delivering a CGM Solution that will take glucose monitoring to the next technological level”

Glucovation, Inc. and DexCom, Inc. have agreed to settle their respective lawsuits against one another on mutually agreeable terms, and on April 22, 2016 an Order of the Court allowing the Complaint and Cross-Complaint to be dismissed with prejudice.

Glucovation is continuing its development effort to commercialize a calibration free Continuous Glucose Monitor system in the 2017 time frame. The company has successfully completed another round of equity financing which will allow it to aggressively move forward towards clinical trials both domestically and abroad. Robert Boock, CEO of Glucovation said, “We are very excited about this recent settlement with Dexcom as it will allow us to execute on our vision of delivering a CGM Solution that will take glucose monitoring to the next technological level”.

Glucovation is a developer of novel Continuous Glucose Monitoring systems with an emphasis on metabolic sensor technologies that will be unmatched in the industry. Its proposed products present a game changing offering that will allow for broader access by an ever-growing need in the diabetes space. The company operates its headquarters in Carlsbad, CA. For more information please visit us at http://www.glucovation.com.

The settlement described in this communication refers to case# 37-2014-00018216-CU-BC-CTL filed in the San Diego Superior Court.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Fernando Corona
Visit website